home / stock / bioaf / bioaf news

BIOAF News and Press, Bioasis Technologies Inc From 01/19/23

Stock Information
Company Name: Bioasis Technologies Inc
Stock Symbol: BIOAF
Market: OTC
Website: bioasis.us
Menu
BIOAF BIOAF Quote BIOAF Short BIOAF News BIOAF Articles BIOAF Message Board
Get BIOAF Alerts

News, Short Squeeze, Breakout and More Instantly...
BIOAF - Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending November 30, 2022

NEW HAVEN, Conn., Jan. 19, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epi...
BIOAF - Bioasis Technologies Inc. Mails Management Information Circular for Annual and Special Meeting of Securityholders

NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epi...

BIOAF - Bioasis Technologies Inc. Announces Amendments to Arrangement Agreement with Midatech Pharma plc

NEW HAVEN, Conn., Dec. 19, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epi...

BIOAF - Bioasis Technologies Inc. Announces Shareholder Webinar

NEW HAVEN, Conn., Dec. 14, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI) (OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal ...
BIOAF - Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc

NEW HAVEN, Conn., Dec. 13, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epi...

BIOAF - Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2022

NEW HAVEN, Conn., Oct. 28, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on e...

BIOAF - Bioasis Technologies Inc. Announces Stock Option Grants

NEW HAVEN, Conn., Aug. 08, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epide...
BIOAF - Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

Phase 2 ready assets transform Bioasis into a clinical stage company with a multi-asset pipeline focused on rare and orphan drug indications Unique approach to neurodegeneration targeting remyelination Initial indications Chronic Inflammatory Degenerative Polyneuropathy, G...

BIOAF - Bioasis Technologies GAAP EPS of -C$0.04, revenue of C$0.04M

Bioasis Technologies press release (OTCQB:BIOAF): FY GAAP EPS of -C$0.04. Revenue of C$0.04M (-99.0% Y/Y). For further details see: Bioasis Technologies GAAP EPS of -C$0.04, revenue of C$0.04M

BIOAF - Bioasis and Neuramedy Enter into Research Collaboration and License Agreement

NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. . (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary xB 3TM platform technology for the delivery of therapeutics a...
Previous 10 Next 10